1. Pink Sheet
  2. >>Vaccines

Instilling Public Trust in COVID Vaccine Allocation Plan: Gov’t Hopes Outside Scientists Will Help

 
• By Sarah Karlin-Smith

National Academy of Medicines is developing a framework for equitable COVID-19 vaccine distribution which, CDC and NIH hope, will help shore up public trust ahead of the unenviable task of having to decide who should be the first to get limited vaccine resources. CDC Director Robert Redfield said the distribution strategy should help lessen the health disparities seen with COVID-19 infections.

Washington D.C., USA - March 1, 2020: National Academies of Sciences sign in Washington D.C., USA.
The National Academy of Medicines is being tasked with devising an equitable COVID-19 vaccine distribution plan • Source: Shutterstock

US National Institutes of Health and Center for Disease Control and Prevention leadership are engaging the National Academy of Medicines to develop a framework for equitable COVID-19 vaccine distribution to shore up public trust ahead of what they anticipate will be a controversial process to allocate initially scarce resources.

The National Academy of Medicines committee is tasked with devising a framework that will help CDC’s Advisory Committee on Immunization Practices develop recommendations on the use of vaccines for American civilians

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Vaccines

US FDA Vaccine Framework Coming In Weeks, But Details Vague

 
• By Sarah Karlin-Smith

New CBER Director Prasad will "unleash a massive" framework on vaccines, FDA Commissioner Marty Makary said 15 May, raising questions about the impact on products nearing approval.

FDA Use Of Artificial Intelligence Will Help US Retain Biotech Leadership

 
• By Sue Sutter and Derrick Gingery

At a House subcommittee hearing, HHS Secretary Robert F. Kennedy Jr. rebutted lawmaker concerns that NIH cuts will drive research and scientists to other countries and said he does not want to advise parents on vaccinating children for measles, chickenpox or polio.

Safety Review Prompts EMA to Suspend Ixchiq Chikungunya Vaccine For Seniors

 
• By Neena Brizmohun

The European Medicines Agency is investigating whether Valneva’s Ixchiq is safe to use in the elderly, following reports of 17 serious adverse events, including two cases resulting in death, in people aged 62 to 89 years who received the vaccine. This follows actions by US and French authorities last month regarding Ixchiq’s use in people over 65.

FDA Adcomms Are Back: Four Cancer Drugs, COVID-19 Vaccine Formulations To Get Reviews

 
• By Sue Sutter and Bridget Silverman

The Oncologic Drugs Advisory Committee will meet for two days in mid-May, followed by a Vaccines and Related Biological Products Advisory Committee’s review of the 2025-2026 COVID-19 vaccine formulation.

More from Pink Sheet

US FDA Vaccine Framework Coming In Weeks, But Details Vague

 
• By Sarah Karlin-Smith

New CBER Director Prasad will "unleash a massive" framework on vaccines, FDA Commissioner Marty Makary said 15 May, raising questions about the impact on products nearing approval.

Managed Access Agreement Fails To Help BioMarin’s Brineura Secure Routine Reimbursement In England

 
• By Francesca Bruce

BioMarin’s ultra-rare disease drug Brineura has breached cost-effectiveness thresholds for highly specialized treatments in England and looks set to be denied routine funding on the National Health Service.

Inclusive By Design: UK Pilots Diversity Plans For Drug & Device Trials

 
• By Vibha Sharma

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.